Skip to content
HomeOur CompanyOur societal impact Global Health Equity Johnson & Johnson proud to join new global coalition to expand diagnosis and treatment of HIV

Johnson & Johnson proud to join new global coalition to expand diagnosis and treatment of HIV

Share Article
share to

Today, Johnson & Johnson announced its commitment to the newly launched MenStar Coalition, a global initiative that will expand the diagnosis and treatment of HIV infections in men. The program aims to break the cycle of HIV transmission and ultimately end the AIDS epidemic as a public health threat by 2030, particularly in sub-Saharan Africa.

Announced by Sir Elton John and the Duke of Sussex at the 2018 International AIDS Conference in Amsterdam, the MenStar Coalition brings together a diverse group of global partners including the Elton John AIDS Foundation, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Children’s Investment Fund Foundation (CIFF), Johnson & Johnson, and Gilead Sciences.

Paul Stoffels, M.D., Vice Chair of the Executive Committee and Chief Scientific Officer, Johnson & Johnson attended the conference and said:

“Breakthrough innovation has enabled us to prevent HIV transmission by reducing the virus in the blood to undetectable, and therefore untransmitable, levels. Our goal in supporting this pioneering program is to break a major cycle of transmission among men by ensuring that young men infected with HIV are diagnosed and treated so they can stay healthy and prevent transmission. This program, along with our other efforts from prevention to cure, are part of our 25-year commitment to change the trajectory of the HIV epidemic and ultimately make HIV history.”

Further details on the MenStar Coalition and the various global partners is available here.

Prince Harry, Elton John and Ndaba Mandela introduce MenStar at the International AIDS Conference

You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.